Email this article Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer
- Authors: Sidorenko Y.S.1, Kit O.I.1, Lisutin A.E.1, Semiletkin O.M.1
-
Affiliations:
- Rostov Cancer Research Institute, Ministry of Health and Social Development of the Russian Federation, Rostov-on-Don
- Issue: No 4 (2010)
- Pages: 24-27
- Section: MAMMOLOGY. TREATMENT
- Published: 29.11.2010
- URL: https://ojrs.abvpress.ru/ojrs/article/view/264
- DOI: https://doi.org/10.17650/1994-4098-2010-0-4-24-27
- ID: 264
Cite item
Full Text
Abstract
Objective: to study hormone balance changes caused by various options of neoadjuvant chemotherapy (CT) in patients with breast cancer (BC).
Materials and methods. Data on 200 patients aged 30 to 65 years with primary BC (Stages IIB-IIIA), who had been treated at the Rostov Cancer Research Institute in 2006 to 2009, served as a material for the study. The levels of steroid hormones of the estrogenic, androgenic, and glucocorticoid series were studied before and after neoadjuvant CT.
Results. When neoadjuvant poly-CT (PCT) was performed on automedia, the levels of total estrogens were almost unchanged; the frac- tions of estrone and estriol also remained stable. Only estradiol levels were recorded to show a certain declining tendency.
There were considerable changes in the expression of all steroid hormones during preoperative systemic PCT.
According o the drug therapy option, significant differences were found in the time course of changes in blood cortisol levels.
Conclusion. Neoadjuvant CT on automedia results in diminished estrogenization irrespective of age and the phase of the menstrual cycle.
Keywords
About the authors
Yu. S. Sidorenko
Rostov Cancer Research Institute, Ministry of Health and Social Development of the Russian Federation, Rostov-on-Don
Author for correspondence.
Email: rnioi@list.ru
Russian Federation
O. I. Kit
Rostov Cancer Research Institute, Ministry of Health and Social Development of the Russian Federation, Rostov-on-DonRussian Federation
A. E. Lisutin
Rostov Cancer Research Institute, Ministry of Health and Social Development of the Russian Federation, Rostov-on-DonRussian Federation
O. M. Semiletkin
Rostov Cancer Research Institute, Ministry of Health and Social Development of the Russian Federation, Rostov-on-DonRussian Federation
References
Supplementary files
